<DOC>
	<DOC>NCT00664170</DOC>
	<brief_summary>The purpose of this study is to compare an injectable emulsion form of docetaxel to Taxotere in patients with advanced cancer.</brief_summary>
	<brief_title>A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Over 18 years old. Advanced cancer potentially sensitive to single agent docetaxel; ie.. locally advanced or metastatic breast cancer, locally advanced nonsmall cell lung cancer, hormone refractory metastatic prostate cancer, other tumor type with no standard treatment. ECOG performance status of 02 and Karnofsky Score of 10070. Patients who have more effective therapy available than single agent docetaxel for the malignancy. Pregnancy or lactation. Intolerance to any antineoplastic agents belonging to the taxoid family. Hypersensitivity to drugs formulated with polysorbate 80. Active infection. Prior anticancer therapy within 30 days prior to the first day of study treatment. Participation in another experimental drug study within 30 days prior to the first day of study treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>